Mental retardation (MR) is clinically and genetically highly heterogeneous. We have done molecular genetic testing on 85 Bulgarian MR patients who were clinically classed as fragile X syndrome (FXS) (n = 32), Rett syndrome (RTT) (n = 36) and Prader-Willi/Angelman syndromes (PWS/AS) (n = 17). We tested for the fragile X MR 1 (FMR1), methyl-CpG binding protein 2 (MECP2), cyclin dependent kinase-like 5 (CDKL5), and Aristaless X (ARX) genes, and did methylation analyses of exon 1 of the small nuclear ribonucleoprotein polypeptide N (SNRPN), and multiplex ligation-dependent probe amplification (MLPA) analyses for large deletions/ duplications, and for the methylation status of FMR1 and SNRPN genes. In the FXS group we only found four mutations in the FMR1 gene (12.5%). In the RTT group we found nine mutations in the MECP2 gene (25.0%) but no CDKL5 gene mutations. In the PWS/ AS group we found nine mutations in the 15q11-q13 region (53%). Thus, we clarified the molecular basis in 26.0% of the patients. The proportion of genetically proved diagnoses in our RTT patients (25.0%) is relatively high and all these cases are due to MECP2 mutations. Despite the type of mutation, all these cases are very similar from the clinical point of view and well recognized in Bulgaria.
INTRODUCTION
Mental retardation (MR) is clinically and genetically highly heterogeneous. Mental retardation and absent speech may be the only clinical finding, or may be associated with progressive neurodevelopmental deficits, seizures, autism and ataxia. A variety of genes, X-linked or autosomal, have been found to be involved in pathogenesis. The most common form of X-linked MR (XLMR) is the fragile X syndrome MR (FXS, OMIM #300624), which is due to an expansion of an unstable CGG repeat in the 5'UTR (5' untranslated region) of the FMR1 (fragile X MR 1) gene. The polymorphic CGG repeat numbers 6 to 54 ± 2 copies in normal individuals, 55 ± 2 to 200 copies in healthy carriers of premutation, and >200 copies in FXS patients [1, 2] .
MENTAL RETARDATION
One of the most common forms of severe MR in females is Rett syndrome (RTT, OMIM#312750), which is mostly due to point mutations or large deletions in MECP2 (methyl-CpG binding protein 2) gene, and rarely in CDKL5 (cyclin dependent kinase-like 5) gene [3, 4] . On the other hand, retarded females with infantile spasms and other early onset seizures could be caused by mutations in the CDKL5 gene [5] . It has been expected that a number of mentally retarded males with epilepsy will be explained by the common mutation dup24 or other mutations in the Aristaless X (ARX) gene [6, 7] .
An autosomal gene mutation that gives rise to common clinical symptoms include Prader-Willi/Angelman syndromes (PWS/AS, OMIM#176270; 105830), due to a deletion of 15q11-q13 or uniparental disomy (UPD) 15 . The CpG islands around exon 1 of the small nuclear ribonucleoprotein polypeptide N (SNRPN) gene are methylated on the maternal chromosome and completely devoid of methylation on the paternal chromosome [8] . This finding is used in developing diagnostic methods for PWS/AS. In case of male patients, PWS can have some clinical aspects of FXS, and in female patients, some clinical aspects of RTT. Here we report clinical/molecular data in a group of 85 Bulgarian patients, out of whom 32 were clinically diagnosed as FXS, 23 as classical RTT, 13 as atypical RTT, 14 as PWS, and three as Angelman syndrome (AS). Some of these patients were discussed elsewhere [9] .
MATERIALS AND METHODS
In total, 85 unrelated patients with MR were included in the study. The clinical diagnoses were as follows: 32 FXS male patients (aged between 2 and 26 years), 36 RTT girls (aged between 2 and 20 years), of whom 23 had classical RTT and 13 atypical RTT [with concomitant diagnosis of autism, epilepsy, and West syndrome (OMIM# 308350)], PWS/AS, Pitt-Hopkins syndrome (OMIM# 610954), 14 PWS (aged between 1 and 11 years), 10 boys and four girls (one of the boys had a concomitant diagnosis of spinal muscular atrophy (SMA, OMIM#253300) and three AS (aged between 4 and 10 years, two girls and one boy). All patients are of Bulgarian ethnicity.
The research protocol was approved by The Ethics Committee for Research Investigations to the Medical University, Sofia, Bulgaria. Informed consent was obtained from the guardians of all patients.
DNA samples were extracted from peripheral blood, using DNA extraction kit (QIAamp DNA Mini Kit; Qiagen, Hilden, Germany). The genetic tests covered the genes FMR1, MECP2, CDKL5, ARX, and methylation analysis of exon 1 of the SNRPN. In addition, multiplex ligation-dependent probe amplification (MLPA) analysis was used to look for large deletions/duplications and to clarify the methylation status of FMR1 and SNRPN genes. The MLPA analysis proved to be useful in clarifying mosaic FXS cases [10] , in detecting large deletions on the X-chromosome genes, as well as in determining the type of mutation (deletion or UPD) in PWS/AS cases.
PROTOCOLS FOR FMR1 GENE ANALYSIS
Betaine-Based-PCR Protocol. The primers used to amplify the CGG repeat in the 5'UTR of the FMR1 gene, the polymerase chain reaction (PCR) mixture and cycling conditions have been described elsewhere [11] . This amplification permits detection of normal and of some premutated alleles. For the correct sizing, PCR products were subjected to electrophoresis on an ABI PRISM™ 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) in the presence of ROX500 size standard (Applied Biosystems).
Methylation Sensitive MLPA (MS-MLPA). The MS-MLPA (SALSA MS-MLPA ME029 probemix) was performed following the manufacturer's instructions (www.mlpa.com). DNA samples diluted in TE buffer (10 mM TrisHCl, pH 7.5; 1 mM EDTA) were subjected to denaturation for 10 min. in denaturing buffer provided by the manufacturer. Hybridization with the FMR1-specific probes and 20 control probes was performed overnight at 60°C. Each sample was divided for the ligation reaction, which is the copy number test (CNT) for deletions/duplications detection, and for the ligation-digestion reaction, the methylation test (MT) for methylation assessment at CpG islands. In both tests, the hybridized probes were ligated by a specific ligase mix, provided by the manufacturer. In the methylation, test the methylation-sensitive restriction enzyme HhaI (Pharmacia Biotech, Uppsala, Sweden) was added. The final step consisted of PCR amplification of the obtained fragments. The PCR buffer, PCR primers, the enzyme dilution buffer and the polymerase were provided in the kit.
The PCR products obtained were analyzed on an ABI PRISM™ 310 Genetic Analyzer (Applied Biosystems) in the presence of ROX500 size standard (Applied Biosystems). All patient samples were analyzed simultaneously with at least two normal male samples and a mutant male carrier of a full mutation.
Copy number changes were determined by comparison to the normal controls. The MT results were easy to interpret as the five FMR1 exon 1 methylation-sensitive fragments (see Figure 1) were absent in the normal controls after HhaI digestion, but were present, as a result of hypermethylation, in a patient carrying a full mutation.
PROTOCOLS FOR MECP2, CDKL5 and ARX GENE ANALYSIS
Sequencing. These X-chromosome genes were directly sequenced, as all the exons (including the first non coding one for the MECP2 gene) and intron/exon splice site borders were included/ covered. The sequence of primers used for PCR amplification was taken from the literature [6, 12, 13] or designed in our laboratory (the primer sequence is available upon request). Standard PCR conditions were applied: primer concentration 0.4 µM, 0.2 mM dNTPs, 0.4 M Betaine (Sigma, St. Louis, MO, USA), 4% DMSO; 1× supplied PCR reaction buffer (Genet Bio, Chungnam, Korea) and 0.5U Prime Taq (Genet Bio). The annealing temperature varied between 55°C and 68°C.
The PCR products were purified by PCR Product Pre-Sequencing Kit (USB, Affymetrix, Inc., Santa Clara, CA, USA) containing 4 U exonuclease I (10 U/µL) and 0.8 U shrimp alkaline phosphatase (2 U/µL). The sequencing reaction was performed MLPA analysis for large deletion/duplication detection along the MECP2 gene. The patient #23 carries the MECP2 deletion of exon 3 and a part of exon 4. All three probes for exon 3 and 3 probes for exon 4 (the numbers of the exons are given above each peak) are deleted in the patient (top) in comparison to the control (bottom). The remaining 2 probes for exon 4 (marked by asterisks) are not deleted and these are the most 3' situated probes along the exon 4. The performed calculations for deletions assessment according to the formula given in "Materials and Methods" showed the following results: relative peak ratios for exon 3 probes were 0.54; 0.41 and 0.37 and for exon 4 probes -0.48; 0.39 and 0.57. Both undeleted exon 4 probes, marked by asterisk showed relative peak ratios 1.04 and 0.94. MLPA analysis. The SALSA MLPA P015-D1 MECP2 probemix was used to screen for large deletions/ duplications along the genes MECP2, CDKL5 and ARX. The analysis was performed following the manufacturer's instructions [14] . Fifty to 200 ng of DNA was diluted in TE buffer to a total volume of 5 µL. The diluted samples were subjected to hybridization with the probes specific for the MECP2, CDKL5 and ARX genes, and 17 control probes. Hybridization was performed overnight at 60°C. Hybridized probes were ligated by a specific ligase mix, provided by the manufacturer. The final step represents PCR amplification of the obtained ligated fragments. The PCR buffer, PCR primers (6-FAM labeled), the enzyme dilution buffer and the polymerase were provided in the kit.
The obtained PCR products were analyzed on an ABI PRISM™ 310 Genetic Analyzer (Applied Biosystems) in the presence of ROX500 size standard (Applied Biosystems). Each patient sample was analyzed simultaneously with at least two normal controls. The relative peak ratios in order to assess deletions were calculated using the formula: r = (peak area patient /mean peak area both neighbouring control peaks patient )/(peak area control /mean peak area both neighbouring control peaks control ). Relative ratio of <0.6 corresponded to a deletion.
PROTOCOLS FOR SNRPN GENE ANALYSIS
Methylation-Specific PCR. DNA was modified by bisulfite treatment using MethylCode Bisulfite Conversion Kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions. The standard protocol was used to amplify maternal methylated and paternal unmethylated alleles [15] . The amplicons were separated in 3% agarose gel and visualized after ethidium bromide staining. The lack of paternal unmethylated fragment (164 bp) leads to PWS, the lack of maternal methylated fragment (131 bp) leads to AS.
Methylation-Sensitive MLPA (MS-MLPA). The MS-MLPA (SALSA MS-MLPA ME028-A1 Prader-Willi/ Angelman probemix) was performed following the manufacturer's instructions [14] . This test is performed as a CNT and a MT in presence of methylation-sensitive restriction enzyme HhaI (Pharmacia Biotech). The protocol is as described above for FMR1 gene. The HhaI cleaves only unmethylated genomic DNA. If the CpG islands are methylated, the HhaI does not digest them; the fragment is amplified by PCR and detected by capillary electrophoresis. If the CpG sites are unmethylated, there is no PCR product in the electrophoretic profile. The CNT permits detection of deletions in PWS/AS cases, while the MT permits clarification of UPD in PWS, as two maternal methylated alleles are present.
RESULTS AND DISCUSSION
The clinical data, genetic tests performed and detected mutations are presented in Table 1 for FXS patients, Table 2 for RTT patients and Table 3 for PWS/AS patients.
FXS. Parents frequently stated that the disease onset has been provoked by severe illnesses, such as whooping cough, pneumonia, recurrent otitis. Sometimes, parents have noticed that their child's development regressed after an infectious disease.
Karyotype analysis showed normal results in all but patient 18 in whom the result was compatible with FXS: 46,fra(X)(q27.3)Y[18]/46,XY [22] .
The PCR protocol failed to detect a normal fragment in three patients (9, 18 and 31 in Table 1 ), MENTAL RETARDATION who were shown to have a hypermethylated CGG pattern by MLPA analysis (Figure 1 ). Their mothers showed single normal alleles and premutated expanded alleles of ~70, ~90 and ~180 CGG repeats, respectively (Figure 2 ) (the results were confirmed by Southern blotting, data not shown). In patient 31, a mosaic pattern normal/premutation/full mutation was detected as a smear located from the zone of normal fragments through the premutated zone to full expansion detected as hypermethylation.
Patient 3 showed a normal allele along the CGG repeated region, but this allele was three repeats longer than the normal allele of his mother, who also carried a premutation of about 90 repeats [10] . The hypermethylated MLPA profile of this patient confirmed a mosaic genotype of full mutation/ normal allele [10] . These results were confirmed by classical Southern blotting (data not shown).
The MLPA CNT did not show any deletion/ duplication on the FMR1 gene. In addition, the MLPA probemix contains 14 specific probes for the FMR2 gene (OMIM #300806), mutations which are associated with fragile X MR E (FRAXE) (OMIM #309584). Both FMR1 and FMR2 genes were simultaneously analyzed by CNT and MT and no pathological changes were detected on the FMR2 gene.
The remaining 28 FXS boys were subjected to genetic tests on the ARX and MECP2 genes. The reason is that mutations in the ARX gene have been associated with MR and epilepsy [6, 7] , but the results from a large series of screened patients have been disappointing [16] . On the other hand, mutations in the MECP2 gene can cause moderate MR and obesity [17] . We detected no mutations in the ARX gene or in the MECP2 gene.
RTT. Twenty-two of the mentally retarded girls in this group were born after a complicated pregnancy and delivery by Caesarean section. Various vaccinations or severe infections were reported by the parents as a triggering factor for disease onset.
Karyotype analysis gave normal results in all but patient 6 who carried a deletion of the short arm of the X chromosome 46,XX,del(X)(p1.22).
Sequencing Figure 3 . The deleted fragments were assessed by the relative peak ratios, calculating the peak area in comparison to the mean peak area of both neighboring control peaks, and compared to the control sample. The relative ratios obtained for the probes in exon 3 and a part of exon 4 were <0.6, which we interpreted as a deletion. The calculated relative peak ratios are provided in the legend to Figure 3 .
We screened for mutations in the CDKL5 gene in 27 patients without success. The PWS/AS as a differential diagnosis in some of the patients (5, 14, 24, 25, 34 and 36) were also excluded.
PWS/AS. Karyotype analysis showed normal results except in patient 17 in whom fluorescent in situ hybridization analysis showed results compatible with deletion: 46,XX,ishdel(15)(q11.2q11.2) (D15S10x1),15p11.2 (D15Z1x2),15q22(PMLx2). The methylation-specific PCR revealed that seven patients lacked the paternal unmethylated fragment (PWS) and that two patients lacked the maternal methylated fragment (AS) (Figure 4 ). To determine more precisely the mutation type (deletion or UPD), we analyzed the nine genetically confirmed cases by MS-MLPA and found six deletions and three to have UPD ( Figures 5A and 5B) . The calculated relative peak ratios in the deletion cases were less than 0.6 and are presented in the legend to Figure 5A .
Eight patients in this group remain with a still unclear molecular defect. The suspected diagnosis of FXS in the male patients was excluded by analysis of the FMR1 gene. The ARX gene was sequenced in the three PWS boys and no mutations were detected. Patient 1 (Table Todorov T 
